Advanced search
3 files | 597.28 KB

Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database

(2012) ANNALS OF THE RHEUMATIC DISEASES. 71(8). p.1355-1360
Author
Organization
Abstract
Objectives: Systemic sclerosis (SSc) is a rare disease requiring multicentre collaboration to reveal comprehensive details of disease-related causes for morbidity and mortality. Methods: The European League Against Rheumatism (EULAR) Scleroderma Trials and Research (EUSTAR) group initiated a database to prospectively gather key data of patients with SSc using a minimal essential dataset that was reorganised in 2008 introducing new items. Baseline visit data of patients who were registered between 2004 and 2011 were analysed using descriptive statistics. Results: In June 2011, 7655 patients (2838 with diffuse cutaneous (dc) and 4481 with limited cutaneous (lc) SSc who fulfilled the American College of Rheumatology diagnostic criteria had been registered in 174 centres, mainly European. The most prominent hallmarks of disease were Raynaud's phenomenon (96.3%), antinuclear antibodies (93.4%) and a typical capillaroscopic pattern (90.9%). Scleroderma was more common on fingers and hands than on any other part of the skin. Proton pump inhibitors (65.2%), calcium channel blockers (52.7%), and corticosteroids (45.3%) were most often prescribed. Among the immunosuppressant agents, cyclophosphamide was used more often in dcSSc than in lcSSc. Conclusions: The EUSTAR database provides an abundance of information on the true clinical face of SSc that will be helpful in improving the classification of SSc and its subsets and for developing more specific therapeutic recommendations.
Keywords
PULMONARY-HYPERTENSION, SYSTEMIC-SCLEROSIS, CRITERIA, RECOMMENDATIONS, PREVALENCE, FREQUENCY, PATTERNS, DISEASE

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 286.16 KB
  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 54.46 KB
  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 256.67 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Meier, Florian MP, Klaus W Frommer, Robert Dinser, Ulrich A Walker, Laszlo Czirjak, Christopher P Denton, Yannick Allanore, et al. 2012. “Update on the Profile of the EUSTAR Cohort: An Analysis of the EULAR Scleroderma Trials and Research Group Database.” Annals of the Rheumatic Diseases 71 (8): 1355–1360.
APA
Meier, F. M., Frommer, K. W., Dinser, R., Walker, U. A., Czirjak, L., Denton, C. P., Allanore, Y., et al. (2012). Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. ANNALS OF THE RHEUMATIC DISEASES, 71(8), 1355–1360.
Vancouver
1.
Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. ANNALS OF THE RHEUMATIC DISEASES. 2012;71(8):1355–60.
MLA
Meier, Florian MP, Klaus W Frommer, Robert Dinser, et al. “Update on the Profile of the EUSTAR Cohort: An Analysis of the EULAR Scleroderma Trials and Research Group Database.” ANNALS OF THE RHEUMATIC DISEASES 71.8 (2012): 1355–1360. Print.
@article{5638696,
  abstract     = {Objectives: Systemic sclerosis (SSc) is a rare disease requiring multicentre collaboration to reveal comprehensive details of disease-related causes for morbidity and mortality.
Methods: The European League Against Rheumatism (EULAR) Scleroderma Trials and Research (EUSTAR) group initiated a database to prospectively gather key data of patients with SSc using a minimal essential dataset that was reorganised in 2008 introducing new items. Baseline visit data of patients who were registered between 2004 and 2011 were analysed using descriptive statistics.
Results: In June 2011, 7655 patients (2838 with diffuse cutaneous (dc) and 4481 with limited cutaneous (lc) SSc who fulfilled the American College of Rheumatology diagnostic criteria had been registered in 174 centres, mainly European. The most prominent hallmarks of disease were Raynaud's phenomenon (96.3%), antinuclear antibodies (93.4%) and a typical capillaroscopic pattern (90.9%). Scleroderma was more common on fingers and hands than on any other part of the skin. Proton pump inhibitors (65.2%), calcium channel blockers (52.7%), and corticosteroids (45.3%) were most often prescribed. Among the immunosuppressant agents, cyclophosphamide was used more often in dcSSc than in lcSSc.
Conclusions: The EUSTAR database provides an abundance of information on the true clinical face of SSc that will be helpful in improving the classification of SSc and its subsets and for developing more specific therapeutic recommendations.},
  author       = {Meier, Florian MP and Frommer, Klaus W and Dinser, Robert and Walker, Ulrich A and Czirjak, Laszlo and Denton, Christopher P and Allanore, Yannick and Distler, Oliver and Riemekasten, Gabriela and Valentini, Gabriele and Mueller-Ladner, Ulf and EUSTAR Co-authors, the and De Keyser, Filip and Smith, Vanessa},
  issn         = {0003-4967},
  journal      = {ANNALS OF THE RHEUMATIC DISEASES},
  keywords     = {PULMONARY-HYPERTENSION,SYSTEMIC-SCLEROSIS,CRITERIA,RECOMMENDATIONS,PREVALENCE,FREQUENCY,PATTERNS,DISEASE},
  language     = {eng},
  number       = {8},
  pages        = {1355--1360},
  title        = {Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database},
  url          = {http://dx.doi.org/10.1136/annrheumdis-2011-200742},
  volume       = {71},
  year         = {2012},
}

Altmetric
View in Altmetric
Web of Science
Times cited: